Medchemexpress

Network Version

N-Desethyl Sunitinib Data Sheet

Product Name: N-Desethyl Sunitinib
CAS No.: 356068-97-8
Cat. No.: HY-10873
MWt: 370.42
Formula: C20H23FN4O2
Purity : >98%
Solubility: DMSO : 6.25 mg/mL (16.87 mM; ultrasonic and warming and heat to 60°C)
Mechanisms: Target: Cancer
Biological Activity:
N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1]. In Vitro: Sunitinib also potently inhibits Kit and FLT-3[1]. Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively[2]. Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner[3]. In Vivo: Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo. Sunitinib (80 mg/kg/day) for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with appr 40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size[2]. Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model[3].

Caution: Not fully tested. For research purposes only

Medchemexpress LLC

www.medchemexpress.com

1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com

Keywords: buy N-Desethyl Sunitinib | N-Desethyl Sunitinib Supplier | purchase N-Desethyl Sunitinib | N-Desethyl Sunitinib cost | N-Desethyl Sunitinib manufacturer | order N-Desethyl Sunitinib | N-Desethyl Sunitinib distributor | N-Desethyl Sunitinib structure buy 356068-97-8 | 356068-97-8 Supplier | purchase 356068-97-8 | 356068-97-8 cost | 356068-97-8 manufacturer | order 356068-97-8 | 356068-97-8 distributor | 356068-97-8 structure